Gilead disclosed that it has a partial clinical hold on two CAR-T cell therapy trials after reports of ICANS (immune effector cell-associated neurotoxicity syndrome). The update indicates regulators and sponsors are responding to safety signals involving neurologic toxicity, a known risk area for CAR-T platforms. The disclosure is notable because it signals a pause without announcing a full program shutdown, suggesting targeted mitigation steps while data are reviewed. For sponsors and investigators, CAR-T enrollment and monitoring timelines may be affected as trial teams implement revised safety procedures. The event adds to ongoing global attention on neurotoxicity management strategies and reinforces how rapidly shifting risk profiles can drive regulatory action in cell therapy programs.